Related Experiment Video
Updated: Jun 5, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3
Hiroshi Nakase1, Silvio Danese2, Walter Reinisch3
1Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
This study identified key circulating biomarkers for ulcerative colitis (UC) and found that filgotinib effectively reduced inflammatory markers, with early changes mediating clinical improvements in UC patients.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Utilized patient samples from the phase 2b/3 SELECTION trial (NCT02914522) to investigate ulcerative colitis (UC) biomarkers.
- Focused on identifying circulating biomarkers and early mediators of filgotinib treatment effects in UC patients.
Purpose of the Study:
- To identify circulating biomarkers associated with ulcerative colitis (UC) severity.
- To explore potential early mediators of filgotinib treatment response in UC patients.
Main Methods:
- Analyzed serum and stool proteins, cell counts, and gene expression factors from UC patients at baseline and during induction.
- Assessed biomarker levels against disease severity (Mayo Clinic Score) and prior biologic treatment status (naive vs. experienced).
- Evaluated filgotinib's effect on biomarkers, specifically week 4 changes mediating week 10 clinical outcomes.
Main Results:
- Systemic inflammatory markers (CRP, IL-6, SAA) and platelet counts strongly correlated with UC disease severity.
- Biologic-experienced patients showed higher levels of inflammatory and neutrophil activation markers compared to biologic-naive patients.
- Filgotinib treatment reduced proinflammatory biomarkers; reductions in SAA, CRP, IL-6, NGAL, and OSM at week 4 mediated improved week 10 clinical scores.
Conclusions:
- Filgotinib significantly modulated circulating biomarkers linked to UC pathology.
- Proinflammatory and neutrophil activation biomarkers identified may serve as early indicators of filgotinib's therapeutic effects in UC.
More Related Videos
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
08:53Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
Published on: July 27, 2022
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Constipation-Predominant IBS